PDCD1 and neoplasm: Currently, a variety of biomarkers are used to evaluate the response of immunotherapy, including tumor mutation burden (12), PD-1, PD-L1, CTLA-4 (13), TIGIT (14), MSI (15), and Neoantigen (16).